Morgan Stanley
CABA icon

Morgan Stanley’s Cabaletta Bio CABA Stock Holding History

Morgan Stanley’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Sell
1,345,526
-62,626
-4% -$206K ﹤0.01% 4349
2026
Q1 		$3.79M Buy
1,408,152
+64,444
+5% +$179K ﹤0.01% 4331
2025
Q4 		$2.94M Sell
1,343,708
-130,968
-9% -$325K ﹤0.01% 4555
2025
Q3 		$3.45M Buy
1,474,676
+149,870
+11% +$257K ﹤0.01% 4427
2025
Q2 		$2.01M Sell
1,324,806
-384,082
-22% -$599K ﹤0.01% 4698
2025
Q1 		$2.37M Buy
1,708,888
+269,723
+19% +$575K ﹤0.01% 4493
2024
Q4 		$3.27M Buy
1,439,165
+610,336
+74% +$2.14M ﹤0.01% 4331
2024
Q3 		$3.91M Buy
828,829
+533,320
+180% +$3.09M ﹤0.01% 4150
2024
Q2 		$2.21M Sell
295,509
-590,195
-67% -$7.23M ﹤0.01% 4498
2024
Q1 		$15.1M Buy
885,704
+110,938
+14% +$2.38M ﹤0.01% 2982
2023
Q4 		$17.6M Buy
774,766
+552,749
+249% +$9.29M ﹤0.01% 3455
2023
Q3 		$3.38M Buy
222,017
+14,656
+7% +$200K ﹤0.01% 4016
2023
Q2 		$2.68M Buy
207,361
+5,005
+2% +$54.3K ﹤0.01% 4230
2023
Q1 		$1.67M Buy
202,356
+2,201
+1% +$20.6K ﹤0.01% 4566
2022
Q4 		$1.85M Buy
200,155
+30,735
+18% +$112K ﹤0.01% 4516
2022
Q3 		$110K Buy
169,420
+47,520
+39% +$57.2K ﹤0.01% 6028
2022
Q2 		$129K Buy
121,900
+22,003
+22% +$31.1K ﹤0.01% 6135
2022
Q1 		$203K Buy
99,897
+49,326
+98% +$129K ﹤0.01% 5919
2021
Q4 		$191K Sell
50,571
-29,347
-37% -$313K ﹤0.01% 6098
2021
Q3 		$972K Sell
79,918
-29,291
-27% -$270K ﹤0.01% 5058
2021
Q2 		$940K Buy
109,209
+85,531
+361% +$840K ﹤0.01% 5113
2021
Q1 		$263K Sell
23,678
-10,384
-30% -$127K ﹤0.01% 5496
2020
Q4 		$425K Sell
34,062
-11,282
-25% -$146K ﹤0.01% 5178
2020
Q3 		$492K Buy
45,344
+8,357
+23% +$96.1K ﹤0.01% 4654
2020
Q2 		$412K Buy
36,987
+31,386
+560% +$240K ﹤0.01% 4699
2020
Q1 		$41K Sell
5,601
-4,729
-46% -$64.8K ﹤0.01% 5543
2019
Q4 		$144K Buy
+10,330
New +$122K ﹤0.01% 5531

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's CABA Position: Q2 2026 in Review

Morgan Stanley reduced its Cabaletta Bio (CABA) stake by 4.4% in Q2 2026, selling an estimated $206K and leaving 1,345,526 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4349.

Morgan Stanley first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $17.6M in Q4 2023. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Morgan Stanley held 1,345,526 shares of Cabaletta Bio worth $4.18M as of Q2 2026.
  • Morgan Stanley sold 62,626 Cabaletta Bio shares in Q2 2026, an estimated $206K.
  • Cabaletta Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4349 holding.
  • Morgan Stanley first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Cabaletta Bio position peaked at $17.6M in Q4 2023.
  • 86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.